HealthPrep on MSN11mon
How To Treat Hunter Syndrome
Hunter syndrome is an exceedingly rare genetic disorder caused by a malfunctioning or missing enzyme. Patients with Hunter ...
Hosted on MSN2mon
DNLI's Hunter Syndrome Drug Gets Breakthrough Therapy Designation
Denali’s wholly owned program, DNL310 or tividenofusp alfa, is an Enzyme Transport Vehicle-enabled iduronate-2-sulfatase (IDS) replacement therapy in development for MPS II (Hunter syndrome).
pharmaphorum7y
Shire's Hunter Syndrome cognitive impairment drug fails
Shire’s attempts to develop a drug for cognitive impairment from the rare inherited disease Hunter Syndrome has failed to produce results. The company’s Elaprase (idursulfase) is already ...
WGNO20d
Project Alive Shines a Light on Rare Disease Week and Rare Disease Day to Raise Awareness for Hunter Syndrome
This annual observance brings attention to the 300 million people worldwide living with rare diseases, including those impacted by Hunter syndrome. Rare Disease Week, held in conjunction with Rare ...
WGN Radio1mon
Denali Therapeutics Announces Primary Analysis and Long-Term Follow-Up of Phase 1/2 Study in Hunter Syndrome (MPS II) with Tividenofusp Alfa
Feb. 06, 2025 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI), today announced the primary analysis of the Phase 1/2 study in 47 participants with Hunter syndrome (MPS II) in the 24-week ...
조선일보1mon
GC Biopharma designates Hunter syndrome treatment as orphan drug in South Korea
GC Biopharma announced on the 5th that the Ministry of Food and Drug Safety has designated the treatment for severe Hunter syndrome, 'Hunterase ICV (intracerebroventricular),' as an orphan drug.